Ex-Nvidia CEO Huang to testify in Congress over China espionage ties
Published 2 d ago13 sourcesEvidence: Reported
The National Security Commission on Emerging Biotechnology warns China is intensifying control over the entire drug supply chain, potentially cutting the US off from future lifesaving treatments. Western pharma firms' heavy investment in Chinese biotechs may hand Beijing leverage over critical technologies, with new Chinese restrictions proposed last month heightening concerns. The warning signals a shift toward treating pharmaceutical supply dependence as a national-security issue, though the specific restrictions and their scope remain unspecified.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Locations
Entities
A US national security commission claims China is increasing its control over the entire pharmaceutical supply chain, from raw materials to finished drugs, potentially creating national security risks for the US and other less self-sufficient nations. This assessment is based on observed Chinese industrial policy and deal-making, not a confirmed event. The specific scope and nature of proposed new Chinese restrictions remain unclear.
Published 2 d ago13 sourcesEvidence: Reported
Published 2 d ago10 sourcesEvidence: Reported
Published 23 h ago7 sourcesEvidence: Reported
Published 2 d ago12 sourcesEvidence: Reported
Published 1 d ago7 sourcesEvidence: Reported
Published 5 h ago4 sourcesEvidence: Reported
Published 1 d ago9 sourcesEvidence: Reported
Published 3 d ago6 sourcesEvidence: Reported